Lanxess, DE0005470405

Lanxess stock gains as Q3 EBITDA rises and 2026 outlook firms

Published on 11/13/2026 at 12:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Lanxess stock gains as the specialty chemicals group reports stronger third-quarter sales and earnings. Management expects full-year EBITDA at the top of its range.

Higher sales, uneven segment performance

  • LANXESS lifted third-quarter sales and EBITDA pre exceptionals despite weak demand in several core markets.
  • Specialty Additives led segment earnings growth, while Consumer Protection and Advanced Intermediates faced margin pressure.
  • Management expects full-year EBITDA pre exceptionals at the upper end of its EUR 450 million to EUR 500 million range.
Lanxess, DE0005470405, Illustration mit AI erstellt.

LANXESS reported stronger sales and earnings for the third quarter on November 5, while cautioning that demand remains weak in important end markets. In its official results release, the specialty chemicals group said higher prices and cost savings supported the quarter.

Lanxess stock traded at 13.45 euros on Lang & Schwarz at 12:10 CET on Friday, November 13, 2026, 1.89 percent above the Xetra close of Thursday, November 12, at 13.20 euros.

Quarterly growth meets weak demand

Third-quarter sales rose 9.6 percent year over year to EUR 1.467 billion, compared with EUR 1.338 billion a year earlier. EBITDA pre exceptionals increased 11.2 percent to EUR 139 million from EUR 125 million, lifting the corresponding margin to 9.5 percent from 9.3 percent.

Free cash flow improved to positive EUR 48 million from negative EUR 14 million in the prior-year quarter. LANXESS attributed the revenue increase primarily to price increases that passed higher raw-material and energy costs on to customers. Improved demand in individual businesses and cost-saving measures also supported earnings.

CEO Matthias Zachert said many core markets still lacked a broad and sustained recovery, particularly agrochemicals, automotive and construction. His comments point to a mixed operating backdrop: pricing and internal measures are cushioning pressure, but volume growth remains dependent on an uncertain industrial cycle.

Specialty Additives drives segment gains

Specialty Additives delivered the strongest earnings improvement. Sales rose 12.7 percent to EUR 569 million, while EBITDA pre exceptionals jumped 57.8 percent to EUR 71 million. Higher selling prices and cost reductions improved the segment margin to 12.5 percent from 8.9 percent.

Consumer Protection increased sales 8.4 percent to EUR 491 million, but EBITDA pre exceptionals fell 6.9 percent to EUR 67 million. The prior-year comparison benefited from a customer contract with a minimum purchase requirement, making the segment decline less indicative of the underlying sales trend than the headline figures suggest.

Advanced Intermediates grew sales 7.2 percent to EUR 404 million, while EBITDA pre exceptionals eased to EUR 25 million from EUR 26 million. LANXESS cited high energy and transportation costs, weak construction and agricultural demand, and low water levels on the Rhine as pressures on profitability.

Guidance moves toward upper end

LANXESS now expects full-year 2026 EBITDA pre exceptionals at the upper end of its EUR 450 million to EUR 500 million range. The company also expects positive free cash flow in the fourth quarter. For investors, the combination of improved cash generation and firm pricing is supportive, but the outlook remains exposed to energy costs and the lack of a broad demand recovery.

LANXESS investor facts

  • Company: LANXESS AG
  • ISIN: DE0005470405
  • Xetra symbol: LXS.DE
  • Business: Specialty chemicals
  • Lang & Schwarz quote: 13.45 euros at 12:10 CET on November 13, 2026
  • Change versus Xetra close: 1.89 percent above the November 12 close of 13.20 euros
  • Third-quarter sales: EUR 1.467 billion, up 9.6 percent year over year
  • Third-quarter EBITDA pre exceptionals: EUR 139 million, up 11.2 percent year over year

Broader market sentiment can be followed in current market reports.

More news and analyses on Lanxess stock are available on the company topic page.

Disclaimer...
en | DE0005470405 | LANXESS | boerse | 70504097 | bgmi